3548 Federal Register / Vol. 87, No. 15 / Monday, January 24, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day-22–1308; Docket No. CDC–2022– 

0007] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Validated Follow-up Interview of 

Clinicians on Outpatient Antibiotic 

Stewardship Interventions. This 

collection aims to perform an interview 

of outpatient clinicians regarding the 

acceptability and perceived clinician 

level barriers associated with our yearlong implementation of interventions 

designed around the Core Elements of 

Outpatient Antibiotic Stewardship. 

DATES: CDC must receive written 

comments on or before March 25, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0007 by any of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

Regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Validated Interview and Survey of 

Outpatient Providers on Antibiotic 

Stewardship Interventions (OMB 

Control No. 0920–1308)— 

Reinstatement—Division of Healthcare 

Quality Promotion (DHQP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Inappropriate antibiotic prescribing is 

a major driver of antibiotic resistance 

which is an urgent national and global 

health threat. Additionally, 

inappropriate antibiotic prescribing 

contributes to avoidable adverse drug 

events that cause substantial harm to 

patients. Most antibiotic prescribing 

originates in traditional outpatient 

settings such as physician offices and 

emergency departments and at least 

30% of these prescriptions are 

completely unnecessary. Over the past 

decade there has been rapid growth in 

non-traditional outpatient settings 

including Urgent Care clinics. Recent 

evidence shows that when compared to 

traditional office settings, inappropriate 

antibiotic prescribing is substantially 

higher in Urgent Care clinics making 

this an important priority for antibiotic 

stewardship. The design, development, 

and evaluation of durable stewardship 

interventions addressing the unique 

setting of Urgent Care clinics is an 

important area of unmet need. This data 

will assess knowledge, attitudes, and 

practices related to antibiotic 

prescribing among clinicians after 

implementation of a year-long Urgent 

Care stewardship initiative. 

CDC requests approval for an 

estimated 62 annual burden hours. 

There is no cost to respondents other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Urgent Care Clinician ........................................ Interview Guide ................................................. 20 1 1 20 

Urgent Care Clinician ........................................ Survey ............................................................... 125 1 20/60 42 

Total ............................................................ ........................................................................... ........................ ........................ ........................ 62 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 15 / Monday, January 24, 2022 / Notices 3549 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–01262 Filed 1–21–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics 

(NCHS), ICD–10 Coordination and 

Maintenance (C&M) Committee 

Meeting 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of virtual meeting. 

SUMMARY: The CDC, National Center for 

Health Statistics (NCHS), Classifications 

and Public Health Data Standards Staff, 

announces the following meeting of the 

ICD–10 Coordination and Maintenance 

(C&M) Committee meeting. This 

meeting is open to the public, limited 

only by audio lines available. Online 

Registration is not required. 

DATES: The meeting will be held on 

March 8, 2022, from 9:00 a.m. to 5:00 

p.m., EST, and March 9, 2022, from 9:00 

a.m. to 5:00 p.m., EST. 

ADDRESSES: This is a virtual meeting. 

Information will be provided on each of 

our respective web pages when it 

becomes available. For CDC/NCHS 

https://www.cdc.gov/nchs/icd/icd10cm_

maintenance.htm. For CMS https://

www.cms.gov/Medicare/Coding/ 

ICD9ProviderDiagnosticCodes/meetings. 

FOR FURTHER INFORMATION CONTACT: 

Traci Ramirez, Medical Systems 

Specialist, CDC, 3311 Toledo Road, 

Hyattsville, Maryland 20782, 

Telephone: (301) 458–4454; Email: 

TRamirez@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The ICD–10 Coordination 

and Maintenance (C&M) Committee is a 

public forum for the presentation of 

proposed modifications to the 

International Classification of Diseases, 

Tenth Revision, Clinical Modification 

and ICD–10 Procedure Coding System. 

Matters To Be Considered: The 

tentative agenda will include 

discussions on ICD–10–CM and ICD– 

10–PCS topics listed below. Agenda 

items are subject to change as priorities 

dictate. Please refer to the posted agenda 

for updates one month prior to the 

meeting. 

ICD–10–PCS Topics 

1. Administration of Spesolimab * 

2. Administration of daratumumab and 

hyaluronidase-fihj * 

3. Administration of Defencath * 

4. Administration of Maribavir * 

5. Administration of Teclistamab * 

6. Administration of Mosunetuzumab * 

7. Administration of afamitresgene 

autoleucel ** 

8. Administration of tabelecleucel ** 

9. Administration of Treosulfan * 

10. Administration of inebilizumab-cdon * 

11. Administration of Xenon-129 * 

12. Administration of betibeglogene 

autotemcel ** 

13. Administration of Omidubicel ** 

14. Implantation of Sphenopalatine Ganglion 

Stimulator for Ischemic Stroke * 

15. Gene Expression Assay ** 

16. Vertebral Body Tethering * 

17. Percutaneous Femoral-Popliteal Artery 

Bypass * 

18. Computer-Assisted Transcranial Magnetic 

Stimulation * 

19. Computer-Aided Analysis for the 

Detection and Classification of Epileptic 

Events * 

20. Facet Replacement Spinal Stabilization 

Device * 

21. Insertion of Sacropelvic Fixation 

System * 

22. Insertion of an Implantable Vagus Nerve 

Stimulation System * 

23. Insertion of a Paired Vagus Nerve 

Stimulation System * 

24. Percutaneous Venous Thrombectomy for 

Postthrombotic Syndrome * 

25. Quantitative Flow Ratio for Non-invasive 

Intraprocedural Analysis of Cardiac 

Angiography 

26. Application of Allogeneic Thymus 

Derived Tissue 

27. Supersaturated Oxygen Therapy 

28. Assistance with Precision Stimulation 

Software * 

29. Section X Updates 

30. Addenda and Key Updates 

* Requestor has submitted a New 

Technology Add-on Payment (NTAP) 

application for FY 2023. 

** Requestor intends to submit an 

NTAP application for FY 2024 

consideration. 

Presentations for procedure code 

requests are conducted by both the 

requestor and CMS during the 

Coordination & Maintenance Committee 

meeting. Discussion from the requestor 

generally focuses on the clinical issues 

for the procedure or technology, 

followed by the proposed coding 

options from a CMS analyst. Topics 

presented may also include requests for 

new procedure codes that relate to a 

new technology add-on payment 

(NTAP) policy request. 

CMS is continuing to modify the 

approach for presenting the new 

technology add-on payment (NTAP) 

related ICD–10–PCS procedure code 

requests that involve the administration 

of a therapeutic agent for the March 8– 

9, 2022 ICD–10 Coordination and 

Maintenance Committee meeting. 

Consistent with the requirements of 

section 1886(d)(5)(K)(iii) of the Social 

Security Act, applicants submitted 

requests to create a unique procedure 

code to describe the administration of a 

therapeutic agent, such as the option to 

create a new code in Section X within 

the ICD–10–PCS procedure code 

classification. CMS will initially only 

display those meeting materials 

associated with the NTAP related ICD– 

10–PCS procedure code requests that 

involve the administration of a 

therapeutic agent on the CMS website in 

early February 2022 at: https://

www.cms.gov/Medicare/Coding/ICD10/ 

C-and-M-Meeting-Materials. 

The 13 NTAP related ICD–10–PCS 

procedure code requests that involve the 

administration of a therapeutic agent 

are: 

1. Administration of Spesolimab * 

2. Administration of daratumumab and 

hyaluronidase-fihj * 

3. Administration of Defencath * 

4. Administration of Maribavir * 

5. Administration of Teclistamab * 

6. Administration of Mosunetuzumab * 

7. Administration of afamitresgene 

autoleucel ** 

8. Administration of tabelecleucel ** 

9. Administration of Treosulfan * 

10. Administration of inebilizumab-cdon * 

11. Administration of Xenon-129 * 

12. Administration of betibeglogene 

autotemcel ** 

13. Administration of Omidubicel ** 

These topics will not be presented 

during the March 8–9, 2022 meeting. 

CMS will solicit public comments 

regarding any clinical questions or 

coding options included for these 13 

procedure code topics in advance of the 

meeting continuing through the end of 

the public comment period, April 8, 

2022. Members of the public should 

send any questions or comments to the 

CMS mailbox at: ICDProcedure 

CodeRequest@cms.hhs.gov by the April 

8, 2022 deadline. 

CMS intends to post a question and 

answer document in advance of the 

meeting to address any clinical or 

coding questions that members of the 

public may have submitted. Following 

the conclusion of the meeting, CMS will 

post an updated question and answer 

document to address any additional 

clinical or coding questions that 

members of the public may have 

submitted during the meeting that CMS 

was not able to address or that were 

submitted after the meeting. 

The NTAP related ICD–10–PCS 

procedure code requests that do not 

involve the administration of a 


jspears on DSK121TN23PROD with NOTICES1